Head-to-head evidence
NNG-DEPO vs Pegmolesatide (HS-20039)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
NNG-DEPO · Stimus
Developed by Nanogen Pharmaceutical Biotechnology
NCT05585645 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.
Pegmolesatide (HS-20039)
Marketed by Hansoh Pharmaceutical Group
NCT03902691 · Phase 3 · completed
This randomized, double-blind trial compared pegmolesatide directly against an active comparator, epoetin alfa, rather than placebo. Its prespecified non-inferiority comparison on hemoglobin change was met, with the between-group difference confidence interval falling entirely within the specified margin.
Next expected readout: December 2026 · NCT07136792 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNG-DEPO's landscape · Pegmolesatide (HS-20039)'s landscape